Track Aardvark Therapeutics, Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Aardvark Therapeutics, Inc. Common Stock AARD Open Aardvark Therapeutics, Inc. Common Stock in new tab

5.47 USD
EPS
-2.53
P/B
0.97
ROE
-48.06
Target Price
29.60 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 12, 2026
EPS-2.53
Book Value5.63
Price to Book0.97
Debt/Equity0.45
% Insiders14.552%
Estimates
Forward P/E-1.40
Forward EPS-3.90
Target Mean Price29.60

DCF Valuation

Tweak assumptions to recompute fair value for Aardvark Therapeutics, Inc. Common Stock (AARD)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Aardvark Therapeutics, Inc. Common Stock Logo Aardvark Therapeutics, Inc. Common Stock Analysis (AARD)

US Healthcare Official Website Stock

Is Aardvark Therapeutics, Inc. Common Stock a good investment? Aardvark Therapeutics, Inc. Common Stock (AARD) is currently trading at 5.47 USD. Market analysts have a consensus price target of 29.60 USD. This suggests a potential upside from current levels.

Earnings Schedule: Aardvark Therapeutics, Inc. Common Stock is expected to release its next earnings report on Aug. 12, 2026. The market consensus estimate for Forward EPS is -3.90.

Investor FAQ

Does Aardvark Therapeutics, Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Aardvark Therapeutics, Inc. Common Stock?

Aardvark Therapeutics, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 12, 2026. The company currently has a trailing EPS of -2.53.

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Exchange Ticker
NASDAQ AARD

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion